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Objectives:  This  study  attempts  to quantify  the  difference  in loss  of quality-adjusted  life expectancy  (QALE)
for  patients  with  operable  and inoperable  non-small-cell  lung  cancer  (NSCLC).
Patients and  methods:  A cohort  consisting  of  1652  pathologically  veriﬁed  NSCLC  patients  with  perfor-
mance  status  0–1 was monitored  for 7 years  (2005–2011)  to  obtain  the  survival  function.  This was  further
extrapolated  to  lifetime,  based  on  the survival  ratios  between  patients  and  age-  and  sex-matched  ref-
erents  simulated  from  the  life  tables  of  the  National  Vital  Statistics  of  Taiwan.  Between  2011 and  2012,
EuroQol  5-dimension  questionnaires  were  used  to  prospectively  measure  the  quality-of-life  (QoL)  of  a
518 consecutive,  cross-sectional  subsample.  We  adjusted  the  lifetime  survival  function  by the  utility  val-
ues  of  QoL  for  the  cancer  cohort  to obtain  the  QALE,  while  that  for the age  and  sex-matched  referents
were  adjusted  to  the values  collected  from  the 2009  National  Health  Interview  Survey,  and the  difference
between  them  was  the  loss-of-QALE.
Results:  The  QALE  for patients  with  operable  and  inoperable  NSCLC  were  11.66  ± 0.18  and 1.43 ±  0.05
quality-adjusted  life  year  (QALY),  with  the corresponding  loss-of-QALE  of 5.25  ±  0.18  and  14.24 ±  0.05
QALY,  respectively.  The  lifetime  utility  difference  for patients  with  operable  and  inoperable  NSCLC  was
9.00 ±  0.18  QALY,  after  adjustment  for QoL  and  lead-time  bias.
Conclusion:  The  utility  gained  from  surgical  operation  for  operable  lung  cancer  is  substantial,  even  after
adjustment  for  lead-time  bias.  Future  studies  should  compare  screening  programs  with  treatment  strate-
gies when  carrying  out cost-utility  assessments  to improve  patients’  values.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Over the past two decades, the mortality attributed to lung can-
er has increased and it is now the leading cause of cancer deaths
1]. Late diagnosis is a fundamental obstacle to improving the out-
omes of lung cancer, with more than 70% of new cases presenting
oo late for curative treatment to be attempted [2]. Owing to the
evelopment of new chemotherapeutic agents, the costs of care
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for inoperable lung cancer are growing rapidly [3]. Therefore, it
is worth examining the lifetime utility difference for patients with
operable and inoperable lung cancer, which emphasizes the impor-
tance of early diagnosis of lung cancer.
For the assessment of lifetime utility difference, both survival
and quality-of-life (QoL) should be taken into consideration, and
thus, the quality-adjusted life year (QALY) unit is more suitable
than estimating survival alone for comparison of various types of
healthcare services [4]. Quality-adjusted life expectancy (QALE) can
be estimated via adjusting the survival function with the mean QoL
at each time point, t, using the following equation [5–7]:
QALE =
∫
E
[
QoL
(
t/x
)]
S
(
t/x
)
dt
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[QoL(t/x)] denotes the expected value of health state (QoL) for
atients with condition x at time t and S(t/x) denotes the survival
unction for condition x at time t.
Previous studies discussing the beneﬁts of surgery mostly
ocused on survival alone, and usually did not take lead-time bias
nto consideration [8]. Based on a 7-year follow-up cohort, this
tudy aims to quantify the difference in loss-of-QALE for patients
ith operable and inoperable non-small-cell lung cancer (NSCLC).
n other words, we attempt to estimate the utility difference after
djustment for QoL and lead-time bias, which might be regained
hrough future screening initiatives.
. Patients and methods
The Institutional Review Board of the National Cheng Kung
niversity Hospital (NCKUH) approved the study before com-
encement (ER-100-079), and every interviewed patient provided
ritten, informed consent. We  abstracted a NSCLC cohort from the
CKUH database of lung cancer for survival analysis, applied the
ational life tables to extrapolate the survival function to lifetime,
rospectively collected the QoL data from a cross-sectional sub-
ample of the cohort, and integrated the lifetime survival with the
oL to estimate the QALE and loss-of-QALE of NSCLC patients using
he QALY unit.
.1. The 7-year follow-up cohort for estimation of the survival
All patients with NSCLC and free from other malignancies dur-
ng the period from January 2005 to December 2011 were recruited
rom the NCKUH lung cancer database. The diagnosis of NSCLC and
ts pathological subtypes were based on histology or cytology. We
eﬁned the tumor stage of each patient by tumor-node-metastasis
lassiﬁcations [9,10]. Patients with tumor stages I, II, IIIA, and
IIB were assessed by experienced thoracic surgeons for tumor
perability. Subjects who underwent pulmonary resections as the
urative treatment were recruited as the operable patients, while
he others belonged to the inoperable group. The thoracic sur-
eons decided whether to perform pulmonary resections or not,
ccording to the practice guidelines [11] as well as each patient’s
ulmonary reserve and co-morbidities. We  used the Eastern Coop-
rative Oncology Group score to classify the performance status
f each patient [12]. The score runs from 0 to 5, with 0 denoting
ully active and 1–5 denoting restricted in physical strenuous activ-
ty, <50% in bed during the day, >50% in bed, bedbound, and dead,
espectively. To avoid selection bias in the operable group, only
atients with performance status 0–1 were evaluated, however, a
ensitivity analysis for subjects with performance status 0–4 was
lso performed. The survival status for each patient was veriﬁed by
ollow-up from the day of diagnosis till the end of 2011.
.2. Extrapolating the survival to lifetime
After obtaining the survival function of the cohort through
aplan–Meier estimate, a method proposed by Huang and Wang
as used to extrapolate the survival function beyond the end of
he follow-up period [13]. This approach assumed that NSCLC gen-
rated a constant excess hazard after the initial follow-up period,
nd its calculation comprised three steps. First, we borrowed the
azard functions from the life tables of the National Vital Statistics
f Taiwan to generate an age- and sex-matched reference popula-
ion by the Monte Carlo method and estimated its survival function.
econd, we calculated the survival ratio between the NSCLC cohort
nd the reference population at each time t and performed a logit
ransformation of the ratio. Third, the logit transformations of the
atios were ﬁtted by simple linear regression up to the end of theer 86 (2014) 96–101 97
follow-up period. The estimated regression line, together with sur-
vival function of the reference population beyond the follow-up
limit, was  used to extrapolate the lifetime survival function of the
NSCLC cohort. The life expectancy of the NSCLC cohort (up to 600
months) after diagnosis was thus estimated. The expected years
of life lost of the NSCLC cohort was  deﬁned as the survival differ-
ence between the cohort and the reference population. The method
described above has been demonstrated by computer simulation
[13] and proven mathematically [14]. It has also been corroborated
by several examples of cancer cohorts [15,16]. An open access soft-
ware, the iSQoL statistical package, was  used for the computation
[17].
2.3. Prospectively measuring the QoL from a cross-sectional
subsample
From May  2011 to April 2012, all consecutive patients with
NSCLC from the outpatient oncology, chest surgery, and chest
medicine departments of NCKUH were invited to participate in
this study. To minimize any magnitude of overestimation of the
QoL, we  also consecutively screened patients admitted to the wards
between November 2011 and January 2012. The inclusion criteria
were realization of a lung cancer diagnosis by each participant, the
absence of malignancy at another site, and each subject’s ability
to understand and answer the questionnaire. In some individuals,
measurements were performed repeatedly; however, each mea-
surement was taken at least 3 months after the previous one.
The 5-dimension EuroQol questionnaire (EQ-5D) [18], the Tai-
wanese version of which has been validated in a previous work [19],
was used with face-to-face interviews to estimate the utility val-
ues of QoL. The ﬁve dimensions assessed by the EQ-5D are mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression,
each of which has three levels of severity. Using the scoring func-
tion from Taiwan, these health state parameters were transformed
into a utility value ranging from 0 to 1, in which 0 represented death
and 1 indicated full health.
The duration-to-date for each measurement was  deﬁned as the
period between the date of NSCLC diagnosis and the date of inter-
view. A kernel-smoothing (i.e., the moving average of the nearby
10%) method was  used to estimate the mean QoL function [6,7]. The
utility values of QoL beyond the follow-up period were assumed to
be the same as the average of the last 10% of patients near the end
of follow-up.
2.4. Estimating the QALE and loss-of-QALE
The lifetime survival function of the NSCLC cohort was adjusted
by the corresponding mean QoL function to obtain a quality-
adjusted survival curve, in which the sum of the area under this
curve was the QALE of NSCLC patients [6]. We  borrowed the EQ-
5D utility values of the age- and sex-matched general population
from the 2009 National Health Interview Survey in Taiwan. After
adjusting the utility values with the survival function of the age-
and sex-adjusted referents, the loss-of-QALE of NSCLC patients was
calculated by subtracting the area under the quality-adjusted sur-
vival curve of NSCLC patients from that of the referents. Since the
referents were age- and sex-matched with every NSCLC case, the
loss-of-QALE would be the expected lifetime utility loss from devel-
oping the disease, and the difference between that of operable and
inoperable NSCLC patients would be the expected lifetime utility
difference after adjustment for lead-time bias.We  further performed a stratiﬁed analysis among patients with
stage IIIA NSCLC using the above methods. The lifetime utility dif-
ference between operable and inoperable stage IIIA patients was
also estimated.
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Fig. 1. Quality-adjusted life expectancy (QALE) of patients with operable (upper
panel) and inoperable (lower panel) non-small-cell lung cancer (NSCLC). The
survival curves (dotted lines), mean utility functions (dashed lines), and quality-
adjusted survival curves (solid lines) of patients with NSCLC are shown, and the
shaded area represents the QALE.8 S.-C. Yang et al. / Lun
.5. Validating the extrapolation method
To validate the extrapolation method, we used the survival data
f patients who were diagnosed during the ﬁrst 4 years and then
xtrapolated them to 7 years through the previously described
ethod. Because these patients were actually monitored until
he end of 2011, the mean survival duration within the 7-year
ollow-up, using Kaplan–Meier method, was considered as the gold
tandard. The relative bias was computed to compare the difference
n values between the extrapolation and Kaplan–Meier estimation.
. Results
A total of 2045 patients visited NCKUH between 2005 and 2011.
ndividuals with incomplete data (n = 20) or no information of per-
ormance status (n = 108, 5 of them received curative operation)
ere not included, leaving 1917 patients for this study. Those with
erformance status 2–4 (n = 265, 16 of them received curative oper-
tion) were then excluded, and thus the cohort for analysis of
urvival function consisted of 1652 patients. The prospectively col-
ected cross-sectional subsample for measuring the QoL consisted
f 518 participants, and 1147 QoL measurements were performed.
able 1 summarizes the characteristics of patients with operable
nd inoperable NSCLC for analysis of survival function and mea-
uring the QoL. Operable patients were 1.6 years younger than
noperable patients (p < 0.05). The operable subsample for QoL had
ore male participants than the inoperable subsample (p = 0.019).
he distributions of tumor stage and comorbidities in each group
f patients were also elucidated.
.1. The QALE and loss-of-QALE
The characteristics of QoL measurements are summarized in
able 2. The utility values of QoL for patients with operable NSCLC
ere higher than those of inoperable patients. Compared with
oung-aged patients, old-aged patients had lower utility values
f QoL. To obtain the quality-adjusted survival curve (Fig. 1), we
ultiplied the survival probability by the mean QoL at each time t
duration-to-date). The sum of the shaded area under the curve
epresents the QALE. Borrowing the utility function of the age-
nd sex-matched referents from the 2009 National Health Inter-
iew Survey in Taiwan, the difference between the area under the
uality-adjusted survival curve of the cancer cohort and that of the
eferents is the loss-of-QALE (Fig. 2). The QALE for patients with
perable NSCLC differed signiﬁcantly from the QALE for patients
ith inoperable NSCLC, as did the loss-of-QALE for the two groups
Table 2). The difference in loss-of-QALE between operable and
noperable NSCLC patients, or, the net difference after adjustment
f potential lead-time bias for age between the two  groups, was
.00 ± 0.18 QALY.
We  conducted a sensitivity analysis for patients with perfor-
ance status 0–4 (Table 2). As patients with performance status
ore than 2 were usually conﬁned to bed and unavailable to answer
he questionnaire, the resulted mean utility values of QoL were sim-
lar to those of patients without including them. The difference in
ALE between operable and inoperable NSCLC patients would be
0.26 QALY, which was not different from that using patients with
erformance status 0–1 alone. However, the difference in loss-of-
ALE would be underestimated slightly (= 8.36 QALY), probably
ecause of the older mean age of inoperable patients. Another sen-
itivity analysis was conducted by only including the utility values
f the ﬁrst QoL measurements of 518 patients in the calculations,
he difference in QALE would be 10.43 QALY and the difference in
oss-of-QALE would be 9.20 QALY for patients with operable and
Fig. 2. Quality-adjusted survival (QAS) curves of patients with operable (upper
panel) and inoperable (lower panel) non-small-cell lung cancer and the corre-
sponding referents. The shaded area between the QAS curve of patients and that of
the corresponding referents is the loss-of-QALE (quality-adjusted life expectancy),
which has been adjusted for lead-time bias (Table 2).
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Table  1
Clinical characteristics of patients with operable and inoperable non-small-cell lung cancer (NSCLC) for outcome research.
Operable NSCLC Inoperable NSCLC
Cohort for survival (n = 479) Subsample for QoL (n = 275) Cohort for survival (n = 1173) Subsample for QoL (n = 243)
Age at diagnosis, mean (SD) year 62.9 (10.6) 61.8 (10.2) 64.5 (13.0) 63.4 (11.8)
Male,  n (%) 260(54.3) 146 (53.1) 683 (58.2) 104 (42.8)
Performance status
0,  n (%) 328 (68.5) 192 (69.8) 752 (64.1) 168 (69.1)
1,  n (%) 151 (31.5) 83 (30.1) 421 (35.9) 75 (30.9)
Tumor stage
I, n (%) 258 (53.9) 164 (59.6) 15 (1.3) 2 (0.8)
II,  n (%) 68 (14.2) 40 (14.6) 8 (0.7) 0 (0)
IIIA,  n (%) 113 (23.6) 49 (17.8) 59 (5.0) 11 (4.5)
IIIB,  n (%) 40 (8.4) 22 (8.0) 218 (18.6) 41 (16.9)
IV,  n (%) 0 (0) 0 (0) 873 (74.4) 189 (77.8)
Comorbiditiesa
CVD/neurodegenerative disease, n (%) 12 (2.5) 3 (1.1) 41 (3.5) 9 (3.7)
Congestive heart failure, n (%) 6 (1.3) 1 (0.4) 22 (1.9) 5 (2.1)
COPD, n (%) 48 (10.0) 23 (8.4) 91 (7.8) 14 (5.8)
Cirrhosis of liver, n (%) 3 (0.6) 3 (1.1) 10 (0.9) 0 (0)
End-stage renal disease, n (%) 4 (0.8) 4 (1.5) 15 (1.3) 1 (0.4)
Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; QoL, quality-of-life; SD, standard deviation.
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Aa Comorbidities were identiﬁed according to the discharge diagnosis prior to the
noperable NSCLC, and these results are not signiﬁcantly different
rom those using repeated measurements.
We also performed a stratiﬁed analysis among patients with
tage IIIA NSCLC (Fig. 3). Compared with inoperable stage IIIA
atients, operable stage IIIA patients had a longer QALE. More-
ver, the loss-of-QALE for operable stage IIIA patients was  greater
han that of inoperable stage IIIA patients, probably because of the
ounger mean age at diagnosis.
.2. Validation of the extrapolation
There were 262 patients with operable and 621 patients with
noperable NSCLC diagnosed during the ﬁrst 4 years, between 2005
nd 2008, of which the survival curves were extrapolated to 2011
nd compared with the Kaplan–Meier estimates based on the 7-
ear follow-up. The relative biases of the extrapolation ranged
etween −4.6% (p = 0.099) and −6.0% (p = 0.116) after 3 years of
xtrapolation (Table 3).
able 2
esults of quality-of-life (QoL) measurements and estimated loss of quality-adjusted life 
Performance status: 0–1 
Operable NSCLC (n = 275) Inoperab
Number of measurements 634 513 
Time  after diagnosis, median (IQR) months 22.1 (11.6–41.5) 12.9 (6
Utility  value of QoL, mean (SD)
Male:
≤54 years 0.86 (0.15) 0.75 (
55–74  years 0.86 (0.16) 0.76 (
≥75  years 0.77 (0.19) 0.67 (
Female:
≤54  years 0.86 (0.16) 0.79 (
55–74  years 0.82 (0.17) 0.74 (
≥75  years 0.72 (0.23) 0.68 (
Tumor stage:
I 0.86 (0.17) – 
II  0.83 (0.17) – 
III  0.83 (0.17) 0.73 (
IV  – 0.75 (
Life  expectancy, mean (SE) years 13.69 (0.09) 1.92 (
QALE, mean (SE) QALY 11.66 (0.18) 1.43 (
Expected years of life lost, mean (SE) years 6.83 (0.09) 17.46 (
Loss-of-QALE, mean (SE) QALY 5.25 (0.18) 14.24 (
bbreviations: IQR, interquartile range; NSCLC, non-small-cell lung cancer; QALY, quality-osis of NSCLC.
4. Discussion
Although the QoL for NSCLC patients has been measured previ-
ously in several studies [20,21], integrating the survival with utility
values of QoL to estimate the lifetime utility difference between
patients with operable and inoperable NSCLC has never been com-
prehensively evaluated. In our study, the utility values of QoL for
patients with operable and inoperable NSCLC were stratiﬁed into
different age bands (Table 2), which show that compared with inop-
erable patients, operable patients had mean utility values closer
to those for the general population (0.96, 0.93, 0.86 for men  ≤54
years, 55–74 years, ≥75 years and 0.96, 0.91, 0.78 for women ≤54
years, 55–74 years, ≥75 years, respectively). In addition, we quan-
tiﬁed the difference in loss-of-QALE (9.00 ± 0.18 QALY), which was
adjusted for QoL and lead-time bias, between patients with oper-
able and inoperable NSCLC. Because we limited the subjects to
cases with pathological evidence of NSCLC and monitored them
for 7 years, sex- and age-matched them to reference subjects to
expectancy (QALE).
Performance status: 0–4
le NSCLC (n = 243) Operable NSCLC (n = 281) Inoperable NSCLC (n = 250)
646 528
.1–25.6) 22.1 (11.4–41.5) 12.9 (6.1–26.1)
0.24) 0.86 (0.15) 0.75 (0.24)
0.23) 0.86 (0.16) 0.76 (0.23)
0.31) 0.77 (0.19) 0.64 (0.31)
0.17) 0.86 (0.16) 0.79 (0.17)
0.22) 0.82 (0.17) 0.74 (0.21)
0.24) 0.72 (0.23) 0.68 (0.24)
0.85 (0.17) –
0.83 (0.17) –
0.25) 0.83 (0.16) 0.72 (0.25)
0.22) – 0.75 (0.22)
0.06) 13.54 (0.11) 1.65 (0.04)
0.05) 11.49 (0.19) 1.23 (0.03)
0.06) 6.97 (0.11) 16.99 (0.04)
0.05) 5.40 (0.19) 13.76 (0.03)
adjusted life year; SD, standard deviation; SE, standard error.
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Table 3
Estimates of mean survival durations for 7 years of follow-up using the extrapolation method based on the ﬁrst 4 years of follow-up data compared with the Kaplan–Meier
estimates based on 7 years of follow-up data.
Cohort size 7-Year follow-up
Kaplan–Meier estimate, mean
(SE) months
Estimate using the extrapolation
based on the ﬁrst 4 years of
follow-up, mean (SE) months
Relative bias, % p value
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QOperable 262 63.3 (1.6) 
Inoperable 621 21.7 (0.7) 
bbreviation: SE, standard error.
stimate life expectancy, and adjusted for the utility values of QoL
f an actual cohort and the corresponding referents in a real-world
etting, our estimations were not confound by the preceding fac-
ors. Additionally, validation of our extrapolation method showed
hat the relative biases are small after 3 years of extrapolation. We
hus tentatively conclude that such estimations would be useful for
ifetime utility analysis of cancer under different treatments, and
etection of NSCLC patients at the operable stage would save more
han 9 QALY. Moreover, operable IIIA patients were found to have
 greater loss-of-QALE than inoperable IIIA patients (Fig. 3), which
ight imply a controversy in current practice. Since the sample
ize in the current study is relatively small, we recommend that
uture works matched on propensity scores be conducted to cor-
oborate our results for potential reconsideration of clinical practice
uidelines.
We selected patients with performance status 0–1 to estimate
he differences in survival, QoL, and QALE. As patients with per-
ormance status 2–4 were usually conﬁned to bed and physically
nsuitable for curative operation, including them into the study
ight result in selection bias. Besides, most of them were unableo answer the questionnaire, thus the mean utility values would
e overestimated. A sensitivity analysis including all subjects with
erformance status 0–4 (Table 2) was conducted and corroborated
ig. 3. Quality-adjusted life expectancy (QALE) and loss-of-QALE of patients with
perable (upper panel) and inoperable (lower panel) stage IIIA non-small-cell lung
ancer. The quality-adjusted survival (QAS) curves of patients (solid lines) and the
orresponding referents (dotted lines) are shown. The blank area represents the
ALE, whereas the shaded area represents the loss-of-QALE.60.4 (0.8) −4.6 0.099
20.4 (0.6) −6.0 0.116
our conjectures. The mean utility values for patients with per-
formance status 0–4 were almost the same to those of patients
with performance status 0–1, while the difference in loss-of-QALE
was slightly underestimated because the mean age of the inoper-
able group became older and their loss of life expectancy became
smaller.
Unlike previous studies that applied internationally chosen
life tables together with the experts’ determination of disabil-
ity weights to calculate the disease burden of lung cancer using
disability-adjusted life year (DALY) [22,23], we  applied the national
life tables of Taiwan and a cross-sectional sample of patients for
measurement of QoL to estimate the QALE and loss-of-QALE by
using QALY as the unit. While the DALY method makes interna-
tional comparisons more feasible, the loss-of-QALE allows direct
comparisons of different diagnosis and treatment strategies, and
would likely be more useful for making decisions regarding the
cost-effectiveness of national health policies.
In our cohort, the 5-year survival rates for different stages of
NSCLC (79.9%, 44.1%, 20.2%, and 7.7%, respectively, for stages I,
II, IIIA, and IIIB-IV NSCLC) appeared comparable to those demon-
strated by the National Cancer Institute [24]. However, the utility
values of NSCLC patients in our cross-sectional subsample were
higher than those reported in other studies [20,21], which may
be attributed to several reasons. First, all patients must have per-
formance status 0–1 to be included for analysis and most (86.1%,
446 of 518 patients) of our subjects were recruited from outpa-
tient departments. They were thus less likely to have any severe
adverse effects and would have higher utility values [20]. Sec-
ond, because insight into the diagnosis of lung cancer was one of
the inclusion criteria required by the Institutional Review Board,
the utility values of our patients would usually be higher [25].
Third, we  assumed that patients remained at the same level of
QoL near the end of the follow-up period while extrapolating the
QoL function to lifetime. Such an assumption could result in a
higher QoL value, because the actual utility value usually declines
with age [26]. However, as the life span of lung cancer patients is
short and both groups of patients were treated in the same way,
the difference between them would not be confounded by this
approach.
Several limitations must be acknowledged in this study. First,
since we  used an age- and sex-matched reference population
instead of patients with the same comorbidities, the QoL  and sur-
vival of our patients might be affected by major chronic diseases.
Fortunately, Table 1 shows minor differences in the prevalence
rates for the two  comparison groups and corresponding cross-
sectional subsamples. We  further limited the recruitment to those
with performance status 0–1 and free from other malignancies,
thus the results would not be biased too much. Second, QoL
measurements from some individuals were performed repeatedly.
Nevertheless, as each measurement was  taken at least 3 months
apart and the results using repeated measurements did not differ
from those only including the ﬁrst QoL measurements, the poten-
tial bias would be minimal. Third, the estimation of QALE would
have been more accurate if we  had measured the QoL of every
patient in the cohort repeatedly during the follow-up period. Unfor-
tunately, we were unable to conduct such a study, and thus used a
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onsecutive, cross-sectional subsample of patients who  were
ealthy enough to accept our invitations for interviews.
. Conclusion
In conclusion, we successfully estimated the QALE and loss-
f-QALE of operable and inoperable NSCLC patients. The lifetime
tility gain from surgical operation is 9 QALY after adjusting for
oL and lead-time bias. Future studies may  focus on comparing
creening programs with treatment strategies to obtain the cost-
er-life year and/or cost-per-QALY for technology assessment and
ossible development of cost-effective clinical guidelines.
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